Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Rhea-AI Summary

Agios (Nasdaq: AGIO) announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 8:15 a.m. PST / 11:15 a.m. EST. The presentation will be available via a live webcast on the company’s Investors site under “Events & Presentations.” A replay will be archived on the company website for at least two weeks after the presentation.

Key Figures

Conference date January 14, 2026 Scheduled J.P. Morgan Healthcare Conference presentation

Presentation time PST 8:15 a.m. PST Start time of conference presentation

Presentation time EST 11:15 a.m. EST Start time of conference presentation

Webcast replay duration at least two weeks Duration replay will be archived on company website

Market Reality Check

$27.47 Last Close

Volume Volume 888,447 is 0.55x the 20-day average of 1,618,140, indicating lighter trading ahead of the conference. low

Technical Shares at $27.18 are trading below the 200-day MA of $34.19 and 40.91% under the 52-week high.

Peers on Argus

AGIO slipped 0.15% while close peers showed mixed moves: DNLI -2.34%, IRON +0.66%, TVTX +1.05%, APGE -0.24%, FOLD +0.18%. With no peers in the momentum scanner, trading appears stock-specific rather than a coordinated sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 23	FDA approval	Positive	-1.4%	U.S. FDA approval of AQVESME for anemia in alpha/beta-thalassemia.
Dec 08	Regulatory update	Neutral	-1.6%	FDA decision on mitapivat sNDA delayed, application remains under review.
Nov 19	Clinical trial data	Negative	-50.9%	RISE UP Phase 3 hit hemoglobin endpoint but missed key secondary endpoints.
Nov 03	Conference data	Positive	-7.2%	New mitapivat data in rare blood disorders at ASH 2025 meeting.
Oct 30	Earnings update	Positive	+2.9%	Q3 2025 results with PYRUKYND revenue growth and strong cash balance.

Pattern Detected

AGIO has often seen negative or muted price reactions around otherwise positive clinical and regulatory milestones, suggesting a pattern of market skepticism or profit-taking on good news.

Recent Company History

Over the last few months, AGIO reported several key milestones. On Oct 30, 2025, Q3 results showed rising PYRUKYND revenue and a strong $1.3B cash position, with a modest positive price reaction. Subsequent clinical and regulatory updates, including RISE UP Phase 3 topline data and FDA approval of AQVESME™ on Dec 23, 2025, were fundamentally positive but drew negative reactions, highlighting a tendency for the stock to sell off on good news. Today’s conference appearance fits a pattern of frequent investor updates.

Market Pulse Summary

This announcement highlights AGIO’s upcoming presentation at the high-profile J.P. Morgan Healthcare Conference on January 14, 2026, offering management another platform to discuss its rare disease portfolio and recent FDA approval of AQVESME™. With shares trading below the $34.19 200-day MA and about 40.91% under the $46 52-week high, investors may focus on any incremental clinical, commercial, or capital allocation commentary shared during the webcast and archived replay.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that its management team is scheduled to present at the 44^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 8:15 a.m. PST / 11:15 a.m. EST.

The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.

About Agios: Fueled by Connections to Transform Rare Diseases™
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.

Contacts:

Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
morgan.sanford@agios.com

Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
eamonn.nolan@agios.com

FAQ

When will Agios (AGIO) present at the J.P. Morgan Healthcare Conference in 2026?

Agios will present on January 14, 2026 at 8:15 a.m. PST / 11:15 a.m. EST.

Where can investors watch the Agios (AGIO) live webcast for the January 14, 2026 presentation?

The live webcast will be available on Agios' Investors website under the Events & Presentations tab.

How long will the replay of the Agios (AGIO) J.P. Morgan presentation be available online?

A replay will be archived on the company website for at least two weeks following the presentation.

What time is Agios (AGIO) speaking in Eastern Time at the J.P. Morgan conference?

The presentation is scheduled for 11:15 a.m. EST on January 14, 2026.

Will Agios (AGIO) provide presentation materials or slides at the J.P. Morgan Healthcare Conference?

Presentation materials are typically posted under Events & Presentations on the Investors site; check the company website around the presentation time.

Can international investors access the Agios (AGIO) webcast for the January 14, 2026 presentation?

Yes, the live webcast is accessible via the company’s Investors website; replay will be available for at least two weeks afterward.